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Abstract. Background: Sentinel Lymph Node (SLN) status is strongly related to clinical outcome in melanoma patients. In
this study we investigated the possible association between the presence of activated and/or suppressive Tumour Infiltrating
Lymphocytes (TILs) and SLN status in clinically stage I/II melanoma patients.
Methods: Diagnostic primary melanoma samples from 20 patients with a sentinel lymph node metastasis were compared
to melanoma samples from 20 patients with a negative sentinel lymph node, who were matched for gender, age and Breslow
thickness. Presence of activated Granzyme B positive (GrB+) TILs, presence of suppressive (FoxP3+) TILs and MHC class I
antigen expression on tumour cells were analysed by immunohistochemistry.
Results: FoxP3 and MHC-I expression had no direct bearing on the presence of melanoma metastases in the SLN. Whereas
the presence of activated GrB+ TILs in the primary melanoma had no predictive value for SLN status either, their absence was
strongly associated with the presence of metastasis in the SLN (p = 0.001). While both GrB+ and FoxP3+ TILs could be
detected in SLN metastases, a majority did not display MHC-I expression.
Conclusion: These data support a role for cytotoxic T cells in the prevention of early metastasis of melanoma to the draining
lymph nodes.
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1. Introduction
Fatal outcome in melanoma patients mostly re-
sults from occurrence of distant metastases, which are
usually preceded by lymph node metastases [23,29].
Lymph node metastases develop in the first-line tu-
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mour-draining lymph node, the sentinel lymph node
(SLN). The prognostic value of the SLN status has
been shown in several large studies [3] and the SLN
status is used as a tool for selecting patients for trials on
adjuvant (immune) therapy [20]. The SLN status and
clinical outcome in melanoma patients is known to be
associated with a number of variables, including Bres-
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low thickness, ulceration, location of primary tumour,
lymphatic invasion, gender and age [6,2,24,21].
It has previously been shown that melanomas can
elicit an immune response [15,17] and that tumour
cells can effectively be eradicated in vivo by cytotoxic
activity of MHC class I restricted CD8+ Granzyme B+
(GrB+) T-cells [1]. Proper activation of a CD8+ T-cell
mediated immune response requires antigen to be pre-
sented in the context of the appropriate MHC class I
molecules. When a cell loses expression of MHC
class I molecules, it can no longer be recognized by
CD8+ lymphocytes, but it might become susceptible
to natural killer (NK) cell recognition [14]. Loss of
MHC class I antigen expression has been shown to
be involved in immune escape and tumour progres-
sion [1,18,19] and has been associated with poor clin-
ical outcome [8,11]. In addition, target cell killing by
cytotoxic T-cells (CTLs) requires the help of CD4+
T-helper (Th) cells [4,12] and is negatively regulated
by suppressive regulatory T-lymphocytes. These sup-
pressive T-lymphocytes express the FoxP3 transcrip-
tion factor, which we used in this study as a marker for
detection of suppressive T-lymphocytes [9,30]. FoxP3
is an X-chromosome-linked factor that controls de-
velopment and function of regulatory T-lymphocytes
(Treg). While high expression levels are indeed found
in this specialized CD4+CD25+ T cell subset, FoxP3
expression may also specify immune-suppressive ac-
tivities in activated conventional T cells [9,10].
In a previous study of patients with stage I/II
melanoma we showed that the presence of activated
(i.e. GrB+ and CD8+) Tumour Infiltrating Lympho-
cytes (TILs) predicted favourable outcome. Presence
of these TILs was significantly correlated with expres-
sion of MHC class I antigen on tumour cells [26,27].
These data suggest that the cellular immune response,
although apparently not sufficient to prevent primary
tumour growth, is nevertheless able to prevent the oc-
currence of lymph node and/or distant metastases.
On the basis of these previous observations, we set
out to determine if MHC class I status and the presence
of GrB+ or FoxP3+ T cells in the immune infiltrate
of early-stage primary melanomas might be associated
with the absence or presence of SLN metastases.
2. Materials and methods
2.1. Patient characteristics
Two groups of patients were selected from the
melanoma database of the department of Surgical On-
cology at the VU University medical center based on
the outcome of the SLN procedure to obtain 20 cases
with a positive SLN and 20 cases with a negative SLN.
All patients were diagnosed as stage I/II based on the
Breslow thickness, and underwent a re-excision of the
primary tumour and SLN procedure between Octo-
ber 1994 and September 2001. The 40 patients were
selected to have comparable age, gender distribution
and Breslow thickness to avoid a confounding effect
of these known prognostic parameters. Both groups
included 9 male and 11 female patients. From 12 of
20 patients with a positive SLN, paraffin-embedded tis-
sue of the SLN metastasis was available to detect TIL
populations in the tumour area in the affected sentinel
node. In the remaining 9 patients no material was left
for further analysis.
2.2. Antibodies and immunohistochemistry
Paraffin-embedded 3-µm tissue sections of primary
melanoma excisional biopsies were stained as previ-
ously described [5]. Lymphocytes were characterised
for expression of GrB using monoclonal antibody
(mAb) GrB7 (mouse IgG2a; VU University Medical
Centre, Amsterdam, The Netherlands) specific for hu-
man GrB [13] and for expression of FoxP3 (rat IgG2a,
PCH101; e-Biosciences, San Diego, CA, USA). Ex-
pression of MHC class I antigen on melanoma cells
was investigated using polyclonal antibody β2-micro-
globulin (β2m) (rabbit Ig, A0072 Dako; Heverlee, Bel-
gium), the mAb HCA2 reactive with HLA-A locus
products, and mAb HC10 recognizing HLA-B/C lo-
cus products [22]. For staining with antibodies against
FoxP3 and HLA-B/C, antigen retrieval was performed
with 10 mM Na-citrate (pH 6) and for staining with
antibodies against GrB and HLA-A, retrieval was per-
formed with 10 mM TRIS, 1 mM EDTA (pH 9).
No antigen retrieval was required for staining with
anti-β2m. Following antigen retrieval, primary anti-
bodies were applied and visualization was performed
with either the Envision™ horseradish peroxidase sys-
tem (DakoCytomation, Glostrup, Denmark) for HCA2,
HC10 and β2m, or the Power Vision plus™ system
(Immunologic, Duiven, The Netherlands) for GrB and
FoxP3 staining according to the manufacturer’s in-
structions.
2.3. Interpretation of the immunohistochemical
staining
Two independent observers, including an experi-
enced pathologist and blinded to the SLN status,
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performed scoring of immunohistochemically stained
slides based on at least ten high power fields. A high
power field references the area visible using a 400×
magnification level. Lymphocytes surrounding the tu-
mour served as an internal control for interpretation
of GrB, FoxP3, and MHC class I antigen expression.
The difference between melanoma cells and lympho-
cytes was based on morphological examination. GrB
was used as a marker for activated TILs with cytolytic
ability and FoxP3 was used as a marker for suppres-
sive TILs [16]. GrB+ and FoxP3+ TILs were scored
as either positive (>1 positive TIL per high power
field) or negative (<1 TIL per high power field). Ex-
pression of HLA-A, HLA-B/C and β2m on melanoma
cells was scored semi-quantitatively in steps of 10%
from 0% to 100%. The median percentage of tumour
cells expressing HLA-A, HLA-B/C and β2m was de-
termined. MHC class I expression was considered pre-
served if expression of both HLA-A, HLA-B/C and
β2m was detected on a higher number of the tumour
cells than the median percentage. Cases in which one
of the MHC class I antigen markers was expressed be-
low the median percentage, were categorized as “lost
MHC class I antigen expression”.
2.4. Statistical analysis
All analyses were performed using the SPSS sta-
tistical software (version 12 SPSS, Inc., Chicago, IL).
Differences between the groups were analysed using
Pearson’s χ2 test or Fisher exact test when appropriate.
The Mann–Whitney U -test was used to compare group
means. All p values were based on two-tailed statisti-
cal analysis. p values 0.05 were considered signifi-
cant.
3. Results
3.1. Patients and clinical characteristics
Clinical characteristics are listed in Table 1. The
20 patients with a SLN metastasis had a median
follow-up period of 83 (range: 24–147) months and
the 20 patients without a SLN metastasis had a me-
dian follow-up period of 102 (range: 65–137) months.
Thirty-five patients were free of disease at the time of
last follow-up, while one patient in the SLN-positive
group died of a disease-unrelated cause and four pa-
tients had developed distant metastases resulting in
death in two of these patients.
3.2. Presence of sentinel lymph node metastasis
correlates with absence of GrB+ TILs in primary
melanoma excisional biopsies
In 19 out of the 20 patients selected for negative
SLN status, GrB+ TILs (Fig. 1A) were present in the
Table 1
Clinical and primary melanoma characteristics of SLN− and SLN+ patients*
Sentinel lymph node p value
Negative (n = 20) Positive (n = 20)
Patients
Gender (male/female) 9/11 9/11 ns
Median age (years) 49 41 ns
Median follow-up (months) 102 (65–137) 83 (24–147) ns
Median Breslow (± st. dev.) 1.36 (± 0.5) mm 1.32 (± 0.2) mm ns
Primary melanoma excisional biopsies
GrB+ TILs
Absent 1 11 0.001
Present 19 9
FoxP3+ TILs
Absent 8 11 ns
Present 12 9
MHC class I antigen expression
Loss** 13 13 ns
Preserved*** 7 7
∗SLN = Sentinel lymph node.
∗∗Defined as <70% (i.e. median) HLA-A/B/C expression (p9).
∗∗∗Defined as 70% HLA-A/B/C expression (p9).
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Fig. 1. Photographs of images of immunohistochemical staining of TILs. A representative primary melanoma biopsy of a patient with a negative
SLN with: (A) GrB+ TILs and (B) FoxP3+ TILs, and a representative biopsy of a SLN metastasis with: (C) GrB+ TILs and (D) FoxP3+ TILs.
primary tumour. Primary melanomas of 9 patients from
the SLN positive group, however, also contained GrB+
TILs. Thus, a direct association with presence of GrB+
TILs and a negative SLN status was not observed. In
contrast, absence of GrB+ TILs in the primary tumour
was strongly associated with SLN metastasis: primary
melanoma excisional biopsies of 12 patients did not
contain any GrB+ TILs and for 11 of these 12 patients
a metastasis was detected in the SLN (p = 0.001, see
Table 1). While an inverse correlation between sup-
pressive FoxP3+ T cells and GrB+ effector T cells
might a priori have been expected, the opposite was
actually found: primary melanomas with GrB+ TILs
most often also harboured FoxP3+ TILs (Fig. 1B and
Table 2). The expected correlation between the pres-
ence of FoxP3+ TILs in primary tumours and the pres-
ence of metastases in SLN was also not observed (Ta-
ble 1).
3.3. Presence of MHC class I antigen expression on
primary tumour cells does not correlate with
SLN status
Complete loss of MHC class I antigen expression in
the primary melanoma was observed in one case. All
other patients showed expression of the three different
MHC-I markers ranging from 10% to 100%. Based on
the median percentages of positive cells, MHC class I
antigen expression was considered preserved if expres-
sion of HLA-A/B/C and β2m was detected on 70%
of the melanoma cells. No correlation was observed
between preserved MHC class I antigen expression and
either GrB+ T cell infiltration or SLN status (Table 1).
3.4. Both FoxP3+ and GrB+ TILs are frequently
detected In SLN metastases
Paraffin-embedded tissue of the melanoma positive
SLN was available from 12 out of 20 patients with
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Table 2
Expression of MHC class I and presence of GrB+ and FoxP3+ TILs in primary melanoma excisional
biopsies and SLN metastasis
GrB+ TILs absent GrB+ TILs present p value











MHC class I antigen expression ns
Loss∗ 3 3
Preserved∗∗ 0 1
∗Defined as <70% (i.e. median) HLA-A/B/C expression (p9).
∗∗Defined as 70% HLA-A/B/C expression (p9).
a SLN metastasis. In most cases both GrB+ TILs
(Fig. 1C) and FoxP3+ TILs (Fig. 1D) were detected in
the metastatic melanoma area (Table 2). In 7 of these
12 patients MHC class I expression on tumour cells in-
filtrated in the SLN could be determined, while in the
remaining five not enough tumour tissue was left in the
tissue blocks after diagnostic examination to make a
reliable assessment. Of note, in 6 of the 7 evaluable pa-
tients a loss of MHC class I expression was observed.
However, no correlation was found between preserved
MHC class I expression and presence of GrB+ TILs.
4. Discussion
In this study we demonstrate that absence of GrB+
TILs in primary melanoma excisional biopsies is
strongly associated with SLN metastasis, as GrB+
TILs were nearly always (19/20 cases) present in pri-
mary melanoma excisional biopsies of patients with a
negative SLN.
The two groups of patients, either with or with-
out a SLN metastasis, were stratified for relevant co-
variables, i.e. selected for comparable prognostic fac-
tors (Breslow thickness, gender and age). Therefore,
the differences in the cellular immune response as we
describe is this report, are more likely to be associated
with differences in SLN status than with other con-
founding clinical factors. These results are in line with
our previous studies, demonstrating that the presence
of activated GrB+ TILs is strongly associated with a
favourable outcome in clinically stage I/II patients [27]
and may also have a favourable impact on survival in
patients with more advanced melanoma [26]. Further-
more, our data are in accordance with a recent study
demonstrating that absence of CD3+ TILs predicts
SLN metastasis in cutaneous melanoma patients [25].
We hypothesize that when GrB+ TILs are present
in the primary tumour, they are capable of inhibiting
or delaying the occurrence of melanoma lymph node
metastasis. The cellular immune response, however,
is apparently not able to clear the primary tumour it-
self. In a substantial number of cases (9 out of 20)
GrB+ TILs were also observed in the primary tumour
of patients with a SLN metastasis. Although absence
of GrB+ TILs in the primary tumour is associated with
the presence of SLN metastasis, the reverse is there-
fore not true. Apparently, an active cellular immune re-
sponse is not sufficient for prohibiting the spread of
melanoma cells to lymph nodes. In 6 of these 9 patients
the occurrence of a positive SLN status despite pres-
ence of GrB+ TILs in the primary tumour, might be
explained by presence of FoxP3+ suppressive TILs in
the primary tumour. Although it is now accepted that
in humans FoxP3 is not an exclusive marker for nat-
urally occurring regulatory T cells (nTregs) as it can
be expressed by other effector T cells upon activation,
FoxP3+ T-lymphocytes are considered to be generally
suppressive and may be involved in the induction of
immunotolerance in lymph node metastases [28,31].
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While a novel model for the role of GrB in FoxP3+
Treg-mediated suppression of anti-tumour CD8+
T cells has recently been proposed [7], the actual ef-
fector function of GrB in Tregs remains poorly un-
derstood. We were unable to detect GrB and FoxP3
co-localization in TILs in the primary tumour (unpub-
lished data) and found no correlation between FoxP3+
TILs and GrB+ TILs, which supports the assump-
tion that the detected GrB+ TILs are likely not Tregs.
We hypothesize that presence of FoxP3+ suppressive
TILs in the primary tumour, next to GrB+ effector
TILs (both markers of possible activation), might re-
sult in active suppression of the latter and thus facil-
itate tumour escape, despite the presence of immune
effector cells with a GrB-mediated cytolytic potential.
Such local immune suppression might also explain the
presence of apparently ineffective GrB+ TILs in SLN
metastases, since most of these harboured FoxP3+
TILs as well.
Loss (either partial or total) of MHC class I anti-
gen expression was observed in a significant number
of melanomas as described before [8], and is in accor-
dance with our previous results. Loss of MHC class I
antigen expression on melanoma cells was nearly al-
ways associated with a lack of GrB+ TILs (Table 2).
Although no correlation was present between MHC
class I antigen expression and SLN status, a trend for
association with clinical outcome was observed, be-
cause all patients with recurrence of disease (n = 4)
showed loss of MHC class I antigen expression. More-
over, the finding of MHC class I loss in 6 out of 7
SLN metastases is highly suggestive of a role for MHC
class I down-regulation in early immune escape of
melanoma and regional spread to the draining lymph
nodes.
In conclusion, absence of GrB+ TILs in primary
melanoma excisional biopsies is strongly associated
with the presence of SLN metastasis. These data un-
derscore the notion that an activated cellular immune
response is important in preventing melanoma cells
to disseminate to lymph nodes. In addition, absence
of GrB+ TILs in primary melanoma excisional biop-
sies in immunohistochemistry might be used to pre-
dict presence of SLN metastasis. Although confirma-
tion in a larger number of patients is clearly needed, the
absence of GrB+ TILs might prove a useful diagnos-
tic tool to distinguish patients with invasive melanoma
that might benefit from immediate full regional lymph
node dissection.
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